Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04842370

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Relapsed or Refractory Acute Myeloid Leukemia Clinical Trial

Official title:
A Prospective, Phase Ia/Ib, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FLT3 Inhibitor, PHI 101, Alone in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Summary

The purpose of this study is to find out the maximum tolerable dose and safety of PHI-101, novel FLT3 inhibitor in the treatment of relapsed or refractory AML for patients who have received standard therapy or cannot tolerate standard therapy, and/or for whom no standard therapy exists. There will be two parts to the study, which we will call Phase Ia and Phase Ib. Phase Ia is called the dose escalation. Approximately 20 to 24 patients are planned to be enrolled into Phase Ia. Phase 1a is conducted to determine the best dose and schedule of dosing of PHI-101 to be used in Phase 1b. There will be 5 different dose levels of PHI-101 given to patients in Phase Ia. Phase Ib is called the dose expansion. Approximately 14-34 patients (approximately 14-17 patients in each of the 2 cohorts planned) of each cohort are planned in Phase Ib based on study design. Phase Ib is also being conducted to assess anti-leukemia response, changes in transfusion requirements, and safety of PHI-101 at the dose level identified during Phase Ia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04842370
Study type Interventional
Source Seoul National University Hospital
Contact Sung-Soo Yoon, MD. PhD
Phone 82-2-2072-3079
Email ssysmc@snu.ac.kr
Status Recruiting
Phase Phase 1
Start date June 8, 2020
Completion date May 21, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04478695 - Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT05038800 - A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) Phase 1
Completed NCT04176393 - A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation Phase 1
Recruiting NCT03850574 - Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Active, not recruiting NCT04666649 - Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Phase 1
Active, not recruiting NCT02675452 - AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05522192 - Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT03755154 - Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT05726110 - Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia Phase 3
Recruiting NCT03765541 - Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia Phase 3
Recruiting NCT05787496 - A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms Phase 1
Terminated NCT02623582 - CD123 Redirected Autologous T Cells for AML Early Phase 1
Withdrawn NCT02215629 - Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia Phase 1